Grant Matthew P, Helsper Charles W, Stellato Rebecca, van Erp Nicole, van Asselt Kristel M, Slottje Pauline, Muris Jean, Brandenbarg Daan, de Wit Niek J, van Gils Carla H
Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht University, 3584 CS Utrecht, The Netherlands.
Department of General Practice, Amsterdam UMC Location University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Cancers (Basel). 2022 Oct 30;14(21):5353. doi: 10.3390/cancers14215353.
In the Netherlands, the onset of the coronavirus pandemic saw shifts in primary health service provision away from physical consultations, cancer-screening programs were temporarily halted, and government messaging focused on remaining at home. In March and April 2020, weekly cancer diagnoses decreased to 73% of their pre-COVID levels, and 39% for skin cancer. This study aims to explore the effect of the COVID pandemic on patient presentations for cancer-related symptoms in primary care in The Netherlands. Retrospective cohort study using routine clinical primary care data. Monthly incidences of patient presentations for cancer-related symptoms in five clinical databases in The Netherlands were analysed from March 2018 to February 2021. Data demonstrated reductions in the incidence of cancer-related symptom presentations to primary care during the first COVID wave (March-June 2020) of -34% (95% CI: -43 to -23%) for all symptoms combined. In the second wave (October 2020-February 2021) there was no change in incidence observed (-8%, 95% CI -20% to 6%). Alarm-symptoms demonstrated decreases in incidence in the first wave with subsequent incidences that continued to rise in the second wave, such as: first wave: breast lump -17% (95% CI: -27 to -6%) and haematuria -15% (95% CI -24% to -6%); and second wave: rectal bleeding +14% (95% CI: 0 to 30%) and breast lump +14% (95% CI: 2 to 27%). Presentations of common non-alarm symptom such as tiredness and naevus demonstrated decreased in-cidences in the first wave of 45% (95% CI: -55% to -33%) and 37% (95% CI -47% to -25%). In the second wave, tiredness incidence was reduced by 20% (95% CI: -33% to -3%). Subgroup analy-sis did not demonstrate difference in incidence according to sex, age groups, comorbidity status, or previous history of cancer. These data describe large-scale primary care avoidance that did not increase until the end of the first COVID year for many cancer-related symptoms, suggestive that substantial numbers of patients delayed presenting to primary care. For those patients who had underlying cancer, this may have had impacted the cancer stage at diagnosis, treatment, and mortality.
在荷兰,新冠疫情爆发后,初级卫生服务的提供方式从面对面咨询发生了转变,癌症筛查项目暂时停止,政府传达的信息重点是居家。2020年3月和4月,每周的癌症诊断病例降至新冠疫情前水平的73%,皮肤癌诊断病例降至39%。本研究旨在探讨新冠疫情对荷兰初级保健中与癌症相关症状患者就诊情况的影响。采用常规临床初级保健数据进行回顾性队列研究。分析了2018年3月至2021年2月荷兰五个临床数据库中与癌症相关症状患者就诊的月度发病率。数据显示,在第一波新冠疫情期间(2020年3月至6月),所有症状综合起来,初级保健中与癌症相关症状就诊的发病率下降了34%(95%置信区间:-43%至-23%)。在第二波疫情期间(2020年10月至2021年2月),发病率没有变化(-8%,95%置信区间-20%至6%)。警示症状在第一波疫情期间发病率下降,在第二波疫情期间发病率持续上升,例如:第一波:乳腺肿块-17%(95%置信区间:-27%至-6%)和血尿-15%(95%置信区间-24%至-6%);第二波:直肠出血+14%(95%置信区间:0至30%)和乳腺肿块+14%(95%置信区间:2%至27%)。常见非警示症状如疲劳和痣的就诊在第一波疫情期间发病率下降,分别为45%(95%置信区间:-55%至-33%)和37%(95%置信区间-47%至-25%)。在第二波疫情期间,疲劳发病率下降了20%(95%置信区间:-33%至-3%)。亚组分析未显示根据性别、年龄组、合并症状态或既往癌症史在发病率上存在差异。这些数据描述了大规模的初级保健回避情况,许多与癌症相关的症状直到新冠疫情第一年年底才有所增加,这表明大量患者推迟了到初级保健机构就诊。对于那些患有潜在癌症的患者,这可能影响了癌症诊断时的分期、治疗和死亡率。